Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction
Pharmaceutics · 22.02.2023 · 15 (3) · 729
DOI: 10.3390/pharmaceutics15030729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.02.2023. Verfasst von Wenqu Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan 43…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key R&D plan of Hubei Province, Shenzhen Science and Technology under Grant.
Abstract (Originalsprache)
Galectin-3 (Gal-3) participates in myocardial fibrosis (MF) in a variety of ways. Inhibiting the expression of Gal-3 can effectively interfere with MF. This study aimed to explore the value of Gal-3 short hairpin RNA (shRNA) transfection mediated by ultrasound-targeted microbubble destruction (UTMD) in anti-myocardial fibrosis and its mechanism. A rat model of myocardial infarction (MI) was established and randomly divided into control and Gal-3 shRNA/cationic microbubbles + ultrasound (Gal-3 shRNA/CMBs + US) groups. Echocardiography measured the left ventricular ejection fraction (LVEF) weekly, and the heart was harvested to analyze fibrosis, Gal-3, and collagen expression. LVEF in the Gal-3 shRNA/CMB + US group was improved compared with the control group. On day 21, the myocardial Gal-3 expression decreased in the Gal-3 shRNA/CMBs + US group. Furthermore, the proportion of the myocardial fibrosis area in the Gal-3 shRNA/CMBs + US group was 6.9 ± 0.41% lower than in the control group. After inhibition of Gal-3, there was a downregulation in collagen production (collagen I and III), and the ratio of Col I/Col III decreased. In conclusion, UTMD-mediated Gal-3 shRNA transfection can effectively silence the expression of Gal-3 in myocardial tissue, reduce myocardial fibrosis, and protect the cardiac ejection function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan 430022, China.
- Hubei Province Clinical Research Center for Medical Imaging, Wuhan 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
ORCID-Profile: Li Zhang, Mingxing Xie
Förderung
- National Natural Science Foundation of China
- Key R&D plan of Hubei Province
- Shenzhen Science and Technology under Grant
- Natural Science Foundation of China
- Key R&D plan of Hubei Province
- Shenzhen Science and Technology
Zitieren
APA
Li, W., Jin, Q., Zhang, L., He, S., Song, Y., Xu, L., Deng, C., Wang, L., Qin, X., & Xie, M. (2023). Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction. Pharmaceutics, 15(3), 729. https://doi.org/10.3390/pharmaceutics15030729
Vancouver
Li W, Jin Q, Zhang L, He S, Song Y, Xu L, et al. Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction. Pharmaceutics. 2023;15(3):729. doi:10.3390/pharmaceutics15030729
BibTeX
@article{Li2023,
author = {Li, Wenqu and Jin, Qiaofeng and Zhang, Li and He, Shukun and Song, Yishu and Xu, Lingling and Deng, Cheng and Wang, Lufang and Qin, Xiaojuan and Xie, Mingxing},
title = {Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {3},
pages = {729},
doi = {10.3390/pharmaceutics15030729}
}
EUVIMED